Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
Upon closing, the Quakertown business will become an independent company called Microsize
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Subscribe To Our Newsletter & Stay Updated
